Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor: A Review of Pharmacodynamics and Clinical Development
Clark AS, Karasic TB, DeMichele A, Vaughn DJ, O'Hara M, Perini R, Zhang P, Lal P, Feldman M, Gallagher M, O'Dwyer PJ. JAMA Oncol. 2015 Dec 3:1-8. | doi: 10.1001/jamaoncol.2015.4701. [Epub ahead of print]
Summary
Palbociclib, a new oral drug whose efficacy in combating breast cancer has been demonstrated alone and in combination with endocrine therapy, also has potential to combat other types of cancer, according to a literature review and additional original research published this month in JAMA Oncology. Co-authors of the study are Drs. Zhang, Lal, and Feldman.
Read the Department of Communications news release.
